Jefferies puts Noven at hold

Noven Pharmaceuticals, Inc. was rated at hold by Jefferies & Co., Inc. analyst David Windley pending the company's earnings call. A key discussion topic is expected to be the Daytrana launch preparation. Jefferies will be looking for the company's pipeline news as well. The analyst lowered his first-quarter earnings-per-share estimate to $0.02 from $0.05, while the earnings-per-share estimate for the full year remains at $0.64. Shares of the Miami, Fla., pharmaceutical company were down 17 cents, or 0.93%, at $18.08 on volume of 128,517 shares versus the three-month running average of 188,168 shares. (Nasdaq: NOVN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.